Day One inks $1.2B biobucks pact for MabCare’s solid tumor ADC

Day One Biopharmaceuticals is offering MabCare Therapeutics up to $1.2 billion for exclusive licensing rights to an antibody drug conjugate (ADC) taking aim at solid tumors in both adults and kids.